Lyme borreliosis vaccine VLA15 tested safe and immunogenic in children and adolescents

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60077344%3A_____%2F25%3A00640237" target="_blank" >RIV/60077344:_____/25:00640237 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1016/S1473-3099(25)00160-4" target="_blank" >https://doi.org/10.1016/S1473-3099(25)00160-4</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S1473-3099(25)00160-4" target="_blank" >10.1016/S1473-3099(25)00160-4</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Lyme borreliosis vaccine VLA15 tested safe and immunogenic in children and adolescents

Popis výsledku v původním jazyce

Lyme borreliosis, known as Lyme disease in the USA, is the most common vector-borne disease in the temperate regions of the northern Hemisphere. It is caused by spirochetes of the Borrelia burgdorferi sensu lato complex and is transmitted by the bite of Ixodes ticks.1, 2 More than 120 000 cases are reported annually by health-care providers, laboratories, and health authorities to official national surveillance systems in Europe (2005–20)3 and more than 33 000 cases are reported in the USA (2008–21).4 However, based on data from insurance claims in the USA, up to 476 000 patients with clinically suspected Lyme borreliosis are diagnosed and treated each year in the USA,5 indicating a potential annual national incidence rate of around 143 cases per 100 000. According to these estimates, the risk of contracting Lyme borreliosis by the age of 77 years (the average life expectancy in the USA) is around 10%, which means that one in 10 people will be infected at least once in their lifetime. Although preventive measures such as the use of repellents, regular self-examinations, and the immediate removal of ticks (within 24 h of attachment) can reduce the risk of infection,6 the number of Lyme borreliosis cases continues to rise, underscoring the urgent need for an effective vaccine.

Název v anglickém jazyce

Lyme borreliosis vaccine VLA15 tested safe and immunogenic in children and adolescents

Popis výsledku anglicky

Lyme borreliosis, known as Lyme disease in the USA, is the most common vector-borne disease in the temperate regions of the northern Hemisphere. It is caused by spirochetes of the Borrelia burgdorferi sensu lato complex and is transmitted by the bite of Ixodes ticks.1, 2 More than 120 000 cases are reported annually by health-care providers, laboratories, and health authorities to official national surveillance systems in Europe (2005–20)3 and more than 33 000 cases are reported in the USA (2008–21).4 However, based on data from insurance claims in the USA, up to 476 000 patients with clinically suspected Lyme borreliosis are diagnosed and treated each year in the USA,5 indicating a potential annual national incidence rate of around 143 cases per 100 000. According to these estimates, the risk of contracting Lyme borreliosis by the age of 77 years (the average life expectancy in the USA) is around 10%, which means that one in 10 people will be infected at least once in their lifetime. Although preventive measures such as the use of repellents, regular self-examinations, and the immediate removal of ticks (within 24 h of attachment) can reduce the risk of infection,6 the number of Lyme borreliosis cases continues to rise, underscoring the urgent need for an effective vaccine.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Lancet Infectious Diseases

ISSN

1473-3099

e-ISSN

1474-4457

Svazek periodika

25

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

2

Strana od-do

951-952

Kód UT WoS článku

001590076000014

EID výsledku v databázi Scopus

2-s2.0-105003584876